A case of a 45-year-old construction worker with a history of intravenous drug use, homelessness, and occasional alcohol and tobacco use.
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), ...
Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...
Fatty liver disease is becoming increasingly common, yet many people still underestimate how serious it can be. Because the condition often develops quietly and without noticeable symptoms in its ...
Health and Me on MSN
Breaking 8 fatty liver myths that are ignored easily
Fatty liver disease is becoming increasingly common, yet many people still misunderstand what causes it and who is at risk. Because the condition often develops silently, it is easy to ignore early ...
Q4 2025 earnings call recap: pemvidutide Phase III MASH plans, Phase II data, FDA status, cash runway to 2028—read now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results